The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
Open accessAbstract
Bacterial translocation (BTL) drives pathogenesis and complications of cirrhosis. Farnesoid X-activated receptor (FXR) is a key transcription regulator in hepatic and intestinal bile metabolism. We studied potential intestinal FXR dysfunction in a rat model of cholestatic liver injury and evaluated effects of obeticholic acid (INT-747), an FXR agonist, on gut permeability, inflammation, and BTL. Rats were gavaged with INT-747 or vehicle during 10 days after bile-duct ligation and then were assessed for changes in gut permeability, BTL, and tight-junction protein expression, immune cell recruitment, and cytokine expression in ileum, mesenteric lymph nodes, and spleen. Auxiliary in vitro BTL-mimicking experiments were performed with Transwell supports. Vehicle-treated bile duct-ligated rats exhibited decreased FXR pathway expression in both jejunum and ileum, in association with increased gut permeability through increased claudin-2 expression and related to local and systemic recruitment of natural killer cells resulting in increased interferon-γ expression and BTL. After INT-747 treatment, natural killer cells and interferon-γ expression markedly decreased, in association with normalized permeability selectively in ileum (up-regulated claudin-1 and occludin) and a significant reduction in BTL. In vitro, interferon-γ induced increased Escherichia coli translocation, which remained unaffected by INT-747. In experimental cholestasis, FXR agonism improved ileal barrier function by attenuating intestinal inflammation, leading to reduced BTL and thus demonstrating a crucial protective role for FXR in the gut-liver axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accordingly, FXR activation by agonists GW4064 or obeticholic acid (OCA) attenuates mucosal injury, ileal barrier permeability, bacterial overgrowth and bacterial translocation in mice and rats 20,21,141,142.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Moreau, R., Jalan, R., Ginès, P., Pavesi, M., Angeli, P., Córdoba, J., Durand, F., Gustot, T., Saliba, F., Domenicali, M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.042 · Cited by 3,041
Self-citationRole of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870 · cited 2×
“FXR deficiency has therefore been linked to increased intestinal permeability and BTL in noneliver-related gastrointestinal disorders, such as inflammatory bowel disease.(25,26) However, whether FXR dysfunction also relates to BTL in chronic liver disease (and also what are the underlying pathophysiological mechanisms…”
BackgroundResultTight Junction Pore and Leak Pathways: A Dynamic Duo
Shen, L., Weber, C. R., Raleigh, D. R., Yu, D., & Turner, J. R. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142150 · Cited by 867
Berg, R. D., & Garlington, A. W. (1979) · Infection and Immunity · doi:10.1128/iai.23.2.403-411.1979 · Cited by 845
Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers.
Madara, J. L., & Stafford, J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113938 · Cited by 758
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Wang, F., Graham, W. V., Wang, Y., Witkowski, E. D., Schwarz, B. T., & Turner, J. R. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62264-x · Cited by 692
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–225 of 225
Pharmacological Options for NASH
Stern, C., & Ratziu, V. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_17
Bile Acids and Bilirubin in Liver Immunology
Zhu, C., Claudel, T., & Trauner, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_7
Rác, M., & Skladaný, Ľ. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.101
Song Lyrics--Gateway to the Interpretation of Poetry.
Saunders, J. (1994) · English in Texas
国家の対外行動分析における国内要因--ネオクラシカル・リアリズムアプローチに向けての一考察
水沢, 紀. (2007) · 政治学研究論集
Zhu, Y., Wang, C., Yu, J., Miao, Y., Chai, Y., Jiang, Z., & Yu, Q. (2021) · Research Square · doi:10.21203/rs.3.rs-1116597/v1
Postoperative liver (dys)function
van Mierlo, K. M. C. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220708km
The FXR agonist obeticholic acid does not stimulate liver regeneration in hepatectomized micePreprint
van Mierlo, K. M. C., Dahrenmöller, C., Lebrun, V., Jansen, P. L. M., Dejong, C. H. C., Leclercq, I. A., Damink, S. W. M. O., & Schaap, F. G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.10.515905
Research Progress on the Effects of FXR on the Development of Colorectal Cancer
钱, 奕. (2024) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2024.144066
Yan, X., Pan, L., Zhao, M., Ma, J., Wang, F., Zhai, X., Xue, Y., Liu, H., Chen, Y., He, Y., et al. (2025) · Aquaculture Reports · doi:10.1016/j.aqrep.2025.103039
Kahale, N. (2019) · theses.fr (ABES) · doi:10.70675/94e9e289z3c99z462bzb7a9z44059acaf7ed
Role of environmental factors on intestinal barrier dysfunctions reported in obesity
Postal, B. G. (2019) · theses.fr (ABES) · doi:10.70675/4b9e7a12ze552z46bez8767z3241d10852d3
Mehta, S., Kurashima, K., Manithody, C., Ohkura, T., Morfin, S., Bagwe, A., Syn, M., Sims, A., Kolli, S., Whalen, C., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.05.024
Hsu, S., Chua, H., Liou, B., Cheng, Y., Lin, C.-R., Chen, Y., Yang, T., Wu, S., Tsuei, D., Chen, H., et al. (2026) · The Journal of Pathology · doi:10.1002/path.70101
Xu, X.-Z., Dong, M.-S., Dai, J.-Y., Wang, Q.-Y., Dong, X.-C., & Jin, Y. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1865281
Li, J., He, Y., Wang, J., Sun, Y., Zhang, L., Liu, L., Li, C., Zhang, G., & Du, P. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109776
Virk, S., Sodhi, R. K., Sharma, A., Sharma, M., Garg, N., Rawat, B., Singh, A., kajla, V., Gupta, S., & Bedi, O. (2026) · Journal of Applied Pharmaceutical Science · doi:10.1177/22313354261472050
Senna, M. M., Shiha, N. A., Zaki, H. F., Ramadan, L. A. A., & Mustafa, A. M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02389-x
Simbrunner, B., Sorribas, M., Schaerer, J., Felber, M., Codinach, J., Rodrigues, S. G., Mandorfer, M., Berzigotti, A., Trauner, M., Reiberger, T., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102037
Nitsotolis, T. N., Assimakopoulos, S. F., Mastoridou, E. M., Kolios, N.-G., Biros, D., Oikonomidi, E.-D., Lagadinou, M., Papalexandrou, A., Milionis, H. J., Christaki, E., et al. (2026) · Cells · doi:10.3390/cells15191739
Sun, L., Chen, H., Fan, W. J., Shi, Z. Y., Zhao, Y., Wang, Y., & Nie, Y. (2026) · Journal of Digestive Diseases · doi:10.1111/1751-2980.70072
Liu, J., Sun, K., Liu, H., Zhu, M., Li, C., He, Y., & Qin, L. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70318
Crosstalk along the gut–liver axis in liver disease: Clinical and mechanistic aspects
Nakamoto, N., Okada, H., Bäckhed, F., Schnabl, B., & Hov, J. R. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.10.019
Metadata
- Authors
- Verbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., Elst, I. V., Windmolders, P., Trebicka, J., Nevens, F., & Laleman, W.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Thomas More Kempen (BE)
- KU Leuven (BE)
- University of Bonn (DE)
- Corresponding author
- Verbeke, Len
- ORCID
- Venue
- The American Journal of Pathology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 185
- Issue
- 2
- Pages
- 409-419
- ISSN
- 0002-9440 (ISSN-L)
- OpenAlex
- W2104582722
- Cited by
- 225
- References
- 54
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 24 · 2023: 11 · 2022: 21 · 2021: 28 · 2020: 18 · 2019: 22 · 2018: 13 · 2017: 18 · 2016: 16 · 2015: 8
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- American Journal Of Pathology (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- Scientific Research–Flanders
- Deutsche Forschungsgemeinschaft (SFB TRR57 project 18)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- obeticholic acid, FXR agonists, bacterial translocation, intestinal barrier dysfunction, cholestasis, bile duct ligation, intestinal permeability, claudin-2, claudin-1, occludin, tight junction proteins, natural killer cells, interferon-gamma, intestinal inflammation, gut-liver axis, liver cirrhosis, Escherichia coli
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Chenodeoxycholic Acid, Cholestasis, Escherichia coli, Gene Expression Regulation, Ileum, Male, Cytokines, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Bacterial Translocation, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
